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Background: Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and
nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab
will be considered for second-line treatment after the failure of anti-PD-1 therapy.
Methods: We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1
therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3mg kg 1 for a
maximum of four doses.
Results: Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (46
months) stable disease. Thirty-five percent of patients developed grade 3–5 immune-related toxicity associated with ipilimumab
therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade
3–5 pneumonitis leading to death in one patient.
Conclusions: Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable
to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including
pneumonitis that warrants close surveillance.
Understanding the molecular basis of immune checkpoint
inhibition is transforming the management of metastatic mela-
noma, and is likely to have a major impact on other cancers
(Hamid et al, 2013). Ipilimumab, a monoclonal antibody that
blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to
potentiate anti-tumour T-cell responses, has been shown to
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prolong overall survival (Hodi et al, 2010; Robert et al, 2011), with
a proportion of patients surviving beyond 5 years (Schadendorf
et al, 2015). The main toxicity seen with ipilimumab is related to
activation of the immune system against autoantigens. Grade 3–4
immune-related adverse events (irAEs) occur in 10%–15% of
patients: primarily skin rash, diarrhoea and colitis, hepatitis and
endocrinopathies (Hodi et al, 2010; Robert et al, 2011). Ipilimumab
is approved by regulatory authorities for the first- and subsequent-
line treatment of metastatic melanoma.
The programmed cell death 1 (PD-1) receptor negatively
regulates the effector phase of T-cell responses after binding to
PD-L1, which is frequently expressed on tumour cells and in the
tumour microenvironment (Rotte et al, 2015). Antibodies blocking
this interaction release the cytotoxic potential of tumour-specific
T-cells. Pembrolizumab and nivolumab, monoclonal antibodies
that bind the PD-1 receptor, have demonstrated significant and
durable tumour responses with manageable toxicity profiles
(Hamid et al, 2013; Topalian et al, 2014; Robert et al, 2015a).
Two recent phase III studies have reported the superiority of
both pembrolizumab and nivolumab to ipilimumab in patients
with advanced melanoma as first-line therapy (Larkin et al, 2015;
Robert et al, 2015b). The Keynote 006 study (NCT01866319)
randomised 834 patients in a 1 : 1 : 1 ratio to receive ipilimumab or
two dosing schedules of pembrolizumab. The estimated 6-month
progression-free survival (PFS) rate was significantly higher for
both pembrolizumab arms as compared with ipilimumab (47.3%,
46.4%, 26.5%, respectively) with estimated 12-month overall
survival rates of 74.1%, 68.4%, 58.2%, respectively (Robert et al,
2015b). The Checkmate 067 study (NCT01844505) evaluated
nivolumab or nivolumab plus ipilimumab vs ipilimumab alone in
945 patients with previously untreated advanced melanoma.
Progression-free survival was significantly longer for nivolumab
alone or combined with ipilimumab compared with ipilimumab
alone (6.9 months, 11.5 months, 2.9 months, respectively) and
objective response rates higher (43.7%, 57.6%, 19.0%, respectively;
Larkin et al, 2015). On the basis of these results, anti-PD-1
antibodies represent a new standard of care in the first-line
treatment of patients with advanced melanoma.
Combination immunotherapy with nivolumab and ipilimumab
is associated with higher objective response rates and PFS
compared with monotherapy ipilimumab. Combination therapy,
however, is associated with significant toxicity with greater than
half of patients experiencing grade 3 or 4 adverse events (Larkin
et al, 2015). It is currently unclear whether combined anti-PD-1
antibody with ipilimumab treatment will be widely adopted due
to concerns about toxicity but the doublet is currently licensed by
the US Food and Drug Administration. In addition, the overall
survival data are not yet reported and this study was not designed
to compare the combination vs nivolumab monotherapy for this
end point (Larkin et al, 2015). For patients who have progressed on
anti-PD-1 therapy, ipilimumab will be a frequent second- or third-
line treatment. Currently, there is very limited evidence regarding
the efficacy and toxicity of ipilimumab after anti-PD-1 antibodies.
We report the clinical efficacy and toxicity profile seen with this
therapeutic sequence in the largest retrospective cohort to date.
MATERIALS AND METHODS
Patient population. We retrospectively identified patients with
advanced melanoma who had sequentially been treated with the
anti-PD-1 antibodies pembrolizumab or nivolumab followed by
ipilimumab. Only patients who had received sequential treatment
were suitable for inclusion. Cases were identified at eight sites in
Australia and two in the United Kingdom. The data collected
included: baseline demographics (age, gender), mutational status
(BRAF/NRAS) and prognostic variables (American Joint Commit-
tee on Cancer (AJCC) stage of disease, lactate dehydrogenase
(LDH), Eastern Cooperative Oncology Group (ECOG) perfor-
mance status); details of the anti-PD-1 inhibitor treatment
(type, dosage, number of cycles received and toxicity) and
ipilimumab treatment (number of cycles and toxicity); data
pertaining to response to respective therapies; time interval
between PD-1 inhibitor treatment and commencement of
ipilimumab; and time to end point data. Progression-free survival
was defined as the time between date of commencement of therapy
to date of progression or death. The response assessments were
assessed according to response evaluation criteria in solid tumors
(RECIST) 1.1 (Eisenhauer et al, 2009) and/or immune-related
response criteria (Wolchok et al, 2009). Severity of adverse events
was graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE) v4.0.
The identified patients all accessed anti-PD-1 therapy through
clinical trials and the schedule and dose received was as per clinical
trial protocol. All the sites had the appropriate ethics approval
for the relevant clinical trial. Subsequent ipilimumab treatment
was at standard dosing (3mg kg 1 intravenously, three weekly to a
maximum of four doses).
RESULTS
Patient demographics and anti-PD-1 therapy. A total of 40
patients were identified who received either pembrolizumab or
nivolumab followed by ipilimumab between November 2012 and
July 2015. The baseline demographic data are detailed in Table 1,
and are consistent with typical melanoma patient populations,
except for the low rate of BRAF mutation positivity (10%), likely
due to selection/eligibility for anti-PD-1 studies. The majority of
Table 1. Baseline characteristics before anti-PD-1 therapy
Total (%); N¼40
Age in years, median (range) 61 (37–79)
Sex
Female 15 (37)
Male 25 (63)
Mutational status
BRAF V600 mutated 4 (10)
Wild-type 36 (90)
AJCC stage
M1a 2 (5)
M1b 4 (10)
M1c 34 (85)
Pre-treated brain metastases at treatment
No 37 (92)
Yes 3 (8)
ECOG performance status
0–1 40 (100)
X2 0
LDH
Normal 24 (60)
Elevated 16 (40)
Prior therapy
BRAFþ /MEK inhibitor 3 (7)
Ipilimumab 4 (10)
Chemotherapy 7 (17)
Other 2 (5)a
Nil 26 (64)
Abbreviations: AJCC¼American Joint Committee on Cancer; ECOG¼Eastern Coopera-
tive Oncology Group; LDH¼ lactate dehydrogenase; PD-1¼programmed cell death-1.
aNilotinib & lenvatinib.
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patients were males (63%) with AJCC stage M1c disease (85%).
All patients had a good performance status before commencement
of anti-PD-1 therapy (ECOG 0–1) and 60% had a normal baseline
LDH. Thirty-six percent of patients had received other systemic
therapy before the commencement of a PD-1 inhibitor. Four (10%)
patients had received ipilimumab as a prior therapy and were
subsequently rechallenged.
Of the 40 patients identified, 26 (65%) received pembrolizumab
at either a dose of 10mg kg 1 on a two or three weekly basis or
2mg kg 1 three weekly and 14 (35%) patients received nivolumab
3mg kg 1 two weekly. All patients discontinued anti-PD 1
inhibitor owing to progression and were treated with ipilimumab
as the next line of systemic therapy.
The median treatment duration on anti-PD-1 therapy and
median PFS were 5 months. Eight (20%) patients achieved
an objective response to anti-PD-1 therapy, 15 (38%) had
stable disease and 17 (42%) had progressive disease as their best
treatment response (Table 2). Three (8%) patients developed grade
3/4 irAEs thought attributable to the PD-1 inhibitor (Table 3).
Efficacy and toxicity of ipilimumab following failure of anti-
PD-1 therapy. The median follow-up for all patients after
commencement of ipilimumab therapy was 12.5 months (range
4–23 months). Four (10%) patients achieved an objective response
to ipilimumab, and an additional 3 (8%) experienced prolonged
stable disease (greater than 6 months) after completion of their
treatment. Thirty-three (82%) patients progressed on therapy
(Table 2). Of the patients who obtained a clinical benefit (objective
response or prolonged stable disease 46 months) from ipilimu-
mab, one (1/17) had previously failed to respond to anti-PD-1
therapy, three patients had stable disease and an additional three
had a partial response as their best treatment response to anti-PD-
1 therapy. Two patients experiencing a clinical benefit experienced
grade 3/4 irAEs. The median interval between the final dose of
PD-1 inhibitor therapy and the first dose of ipilimumab was 53
days (range 2–683 days). The median time between the last dose of
anti-PD-1 therapy and the commencement of ipilimumab therapy
did not significantly differ between patients obtaining a clinical
benefit from ipilimumab and non-responders. The median interval
between therapies was 32 days for those who experienced toxicity.
Only 22 (55%) patients received all the four doses of ipilimumab,
with early termination owing to toxicity (30%) and/or clinical
deterioration (15%).
Fourteen (35%) patients developed grade 3–5 irAEs associated
with ipilimumab therapy (Table 3). Ten percent of these high-
grade irAEs occurred after receiving only one cycle of ipilimumab.
No patients who were rechallenged with ipilimumab experienced a
high-grade irAE, and only one of the five patients achieved an
objective response. The most common high-grade irAE was
diarrhoea or colitis (grade 3/4 23%), all requiring immunosup-
pressive therapies. Other grade 3/4 immune-related toxicities were
hepatitis, pneumonitis and a case of encephalitis. Two (5%)
patients experienced two grade 3/4 iAEs simultaneously (pneu-
monitis and hepatitis, diarrhoea and hepatitis), which required
multiple lines of immunosuppression before improvement was
seen clinically and biochemically. Three (8%) patients developed
grade 3–5 pneumonitis, one of whom died (Figure 1). One patient
recovered fully after a prolonged course of high-dose intravenous
and oral steroids and the third patient required 46 months of
immunosuppression with oral steroids, mycophenolate and
tacrolimus. Two of the 14 (14%) patients who experienced
high-grade irAEs with ipilimumab had developed severe irAEs
(hypothyroidism, bullous pemphigoid) with previous anti-PD-1
therapy.
DISCUSSION
Recent clinical trials have demonstrated superior efficacy of the
anti-PD-1 antibodies pembrolizumab and nivolumab compared
with ipilimumab in the front line treatment of patients with
advanced melanoma establishing these agents as a new standard of
care (Larkin et al, 2015; Robert et al, 2015b).Thirty to forty-five
percent of patients respond to anti-PD-1 therapy with durable
responses in the majority. Nevertheless, a significant proportion of
patients will require second-line therapy, and ipilimumab is the
most likely choice. Although the safety profile for pembrolizumab
in ipilimumab naive and pre-treated patients was similar in the
KEYNOTE-001 study (Daud et al, 2015), and nivolumab has been
tolerated safely as sequential treatment, even after patients have
experienced grade 3 toxicity with ipilimumab (Weber et al, 2013;
Wolchok et al, 2013), there is very limited evidence for the reverse
treatment sequence.
We report on a large cohort of patients that have received
treatment with ipilimumab after failure of anti-PD-1 therapy.
Twenty percent of patients initially obtained an objective response
to anti-PD-1 therapy, a lower response rate than reported in
monotherapy clinical trials. Responses to anti-PD-1 therapy are
usually durable; as this patient cohort was retrospectively identified
as requiring subsequent ipilimumab, it is expected the response
rates would be lower than that in an unselected population. The
biology of innate vs acquired resistance to anti-PD-1 therapy is
likely to be different. Innate resistance to anti-PD-1 therapy, as
seen in the majority of this cohort, may be a poor prognostic
variable or may indicate that alternate approaches to immune
modulation need to be considered.
Twenty percent of patients in our cohort obtained a clinical
benefit (response or prolonged stable disease) from ipilimumab
therapy in keeping with previous reports in patients who have
progressed on anti-PD-1 therapy (Weber et al, 2013). The objective
response rate of 10% is similar to the response rates seen with
ipilimumab in trials in the first- and second-line setting (Hodi et al,
2010; Larkin et al, 2015; Robert et al, 2015b). However, of patients
who progressed through anti-PD-1 inhibitor therapy, only one
responded to subsequent ipilimumab. Overall survival data for this
cohort is immature. Ipilimumab can induce durable responses in
patients who achieve stable disease, as well as those who achieve an
Table 2. Response to treatment
Best overall response–no. (%)
Pembrolizumab,
N¼26 (65%)
Nivolumab,
N¼14 (35%)
Ipilimumab,
N¼40
Complete response 0 0
Partial response 8 (20) 4 (10)
Stable disease 15 (38) 3 (8)
Progressive disease 17 (42) 33 (82)
Table 3. Severe immune-related adverse events
Pembrolizumab,
N¼26 (65%)
Nivolumab,
N¼14 (35%)
Ipilimumab,
N¼40
Grade 3/4 irAEs–no. (%) 3 (8) 14 (35%)
Hypothyroidism–1 Colitis/diarrhoea–9
Panhypopituitarism–1 Pneumonitis–3
Bullous pemphigoid–1 Hepatitis–2
Encephalitis–1
Abbreviation: irAE¼ immune-related adverse event.
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objective response making overall survival a more meaningful end
point to assess the efficacy of ipilimumab (Schadendorf et al, 2015).
The authors acknowledge that response rates alone are insufficient
to make conclusions on the efficacy of ipilimumab after failure of
anti-PD-1 therapy and further prospective studies are required.
However, responses to ipilimumab can be seen even after failure of
anti-PD-1 therapy making it a viable treatment option.
An important finding in this analysis is that grade 3/4 immune-
related toxicity occurred in over a third of patients treated with
sequential ipilimumab following anti-PD-1 therapy, a higher rate
than generally observed with the currently approved dose of
3mg kg 1 ipilimumab (Hodi et al, 2010; Kaufman et al, 2013;
Robert et al, 2015b). Also, increased toxicity did not appear to
correlate with improved response rates, unlike previous reports in
the literature (Downey et al, 2007). Diarrhoea or colitis were
the most common toxicities, followed by hepatitis, consistent with
the known toxicity profile of ipilimumab. Gastrointestinal and
hepatic toxicity typically develops 6–7 weeks following the
commencement of ipilimumab (Weber et al, 2012); however, we
encountered early toxicity, as three patients experienced grade 3
diarrhoea after one cycle of ipilimumab. In this cohort, three
patients experienced grade 3/4 pneumonitis, and one patient died
due to this treatment complication. Pneumonitis has been rarely
described with ipilimumab therapy and is more commonly
reported in association with PD-1 inhibitors (Weber et al, 2015).
Our experience suggests that it is a more frequent irAE
encountered with ipilimumab delivered subsequent to anti-PD-1
therapy.
Pharmacokinetic studies have demonstrated that the mean
elimination half-life of pembrolizumab is 26 days and 17–25 days
for nivolumab, with linear pharmacokinetics (Bristol-Myer Squibb,
2013; Merck, 2014). In addition, flow cytometry has been used to
estimate PD-1 occupancy on circulating T cells over time with
nivolumab. Owing to its high affinity, a mean plateau occupancy of
72% was seen forX59 days after a single dose, suggesting that even
when serum levels are undetectable sufficient concentrations
persist to maintain PD-1 occupancy (Brahmer et al, 2010).
The high rates of toxicity in this group with a median time
between treatments of 32 days may indicate that this is not an
adequate washout period.
In addition, biomarker studies from a phase I study of
nivolumab demonstrated that CTLA-4 positive CD4 T cells were
significantly increased in non-responders after treatment which
could be a potentiating factor for the excess toxicity seen in this
series given that all patients discontinued anti-PD-1 therapy due to
progression (Gibney et al, 2015).
Translational studies using blood samples collected from
patients who have been treated with anti-PD-1 or anti-CTLA-4
agents alone, in combination or sequenced have revealed vastly
different T-cell gene expression profiles between these patient
cohorts (Das et al, 2015). This underscores that a combined
blockade of co-inhibitory T-cell receptors at the same time can lead
to a different immunological outcome than the sequential
engagement of the same receptors. A more detailed understanding
of such dose, sequence and combinatorial differences on immune
and tumour cell function is urgently required to guide selection of
the most mechanistically rational immunotherapy regimen.
Furthermore, the immunological profile induced by anti-PD-1
pre-treatment may increase the autoimmune potential of T cells
that are subsequently activated during anti-CTLA-4 therapy and
hence be a mechanism for increased toxicity.
In keeping with our observation of increased toxicity of
anti-CTLA-4 blockade after anti-PD-1 treatment, a case series
reported on three patients who were treated in the same sequence
and experienced prolonged, difficult-to-treat autoimmune colitis
(Danlos et al, 2015). A further series of patients treated with
sequential therapy reported that three out of five patients
experienced high-grade irAEs, one of which was encephalopathy
in addition to hepatitis (Khoja et al, 2015). There is also some
suggestion that toxicity of vemurafenib may be potentiated by prior
anti-PD-1 therapy ( Johnson et al, 2013; Khoja et al, 2015).
Results of pivotal phase III studies have established PD-1
inhibitors as first-line therapy in advanced melanoma. For those
failing anti-PD-1 therapy, ipilimumab will be a treatment option
for many patients, as borne out by current clinical practice in
patients progressing on PD-1 inhibitors and owing to a lack of
effective therapeutic alternatives outside of clinical trials. However,
our early experience suggests that the toxicity of ipilimumab given
after anti-PD-1 therapy may be greater than is seen in first-line
therapy or after other treatments. For the moment, when treating
with ipilimumab following failure of PD-1 inhibitors, oncologists
should have increased vigilance for severe and potentially early
immune-related toxicity.
Many questions remain unanswered surrounding appropriate
patient selection and predictive biomarkers for immune checkpoint
inhibitors in clinical practice. Greater understanding of the tumour
microenvironment and the process of immune-editing is funda-
mental to allow rational stratification of new immunotherapies and
combinations to achieve optimal responses on an individual basis
(Teng et al, 2015).
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Figure 1. Computer tomography scans demonstrating a severe pneumonitis during ipilimumab therapy; a 61-year-old patient with metastatic
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